Physician profile
Robin Collins Stone
NPI 1992799316
$10,149.52
in general payments reported to CMS, 2019-2025
50 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $1,665 · 2021: $1,704 · 2022: $1,158 · 2023: $1,438 · 2024: $1,530 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,292 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.39 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $965.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $959.60 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $823.60 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $698.25 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $650.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $640.45 | 2019-2025 | Trintellix |
| Pfizer INC. | $638.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.93 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $428.33 | 2019-2025 | Tavneos, Repatha, Otezla |
| Glaxosmithkline, LLC. | $327.52 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $312.93 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Antares Pharma, INC. | $303.71 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Corium, LLC | $232.97 | 2023-2024 | Azstarys, Azstarys |
| Astellas Pharma US INC | $231.87 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $223.25 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.